These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 10681310)
1. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Rose JR; Mullarkey MA; Christ WJ; Hawkins LD; Lynn M; Kishi Y; Wasan KM; Peteherych K; Rossignol DP Antimicrob Agents Chemother; 2000 Mar; 44(3):504-10. PubMed ID: 10681310 [TBL] [Abstract][Full Text] [Related]
2. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Wasan KM; Strobel FW; Parrott SC; Lynn M; Christ WJ; Hawkins LD; Rossignol DP Antimicrob Agents Chemother; 1999 Oct; 43(10):2562-4. PubMed ID: 10508046 [TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Rossignol DP; Wasan KM; Choo E; Yau E; Wong N; Rose J; Moran J; Lynn M Antimicrob Agents Chemother; 2004 Sep; 48(9):3233-40. PubMed ID: 15328078 [TBL] [Abstract][Full Text] [Related]
4. Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Wasan KM; Sivak O; Cote RA; MacInnes AI; Boulanger KD; Lynn M; Christ WJ; Hawkins LD; Rossignol DP Antimicrob Agents Chemother; 2003 Sep; 47(9):2796-803. PubMed ID: 12936976 [TBL] [Abstract][Full Text] [Related]
5. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide. Kawata T; Bristol JR; Rossignol DP; Rose JR; Kobayashi S; Yokohama H; Ishibashi A; Christ WJ; Katayama K; Yamatsu I; Kishi Y Br J Pharmacol; 1999 Jun; 127(4):853-62. PubMed ID: 10433491 [TBL] [Abstract][Full Text] [Related]
6. Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist. Kobayashi S; Kawata T; Kimura A; Miyamoto K; Katayama K; Yamatsu I; Rossignol DP; Christ WJ; Kishi Y Antimicrob Agents Chemother; 1998 Nov; 42(11):2824-9. PubMed ID: 9797210 [TBL] [Abstract][Full Text] [Related]
7. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Bunnell E; Lynn M; Habet K; Neumann A; Perdomo CA; Friedhoff LT; Rogers SL; Parrillo JE Crit Care Med; 2000 Aug; 28(8):2713-20. PubMed ID: 10966240 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686 [TBL] [Abstract][Full Text] [Related]
10. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. Kennedy AL; Wasan KM J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063 [TBL] [Abstract][Full Text] [Related]
12. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Wasan KM; Pritchard PH; Ramaswamy M; Wong W; Donnachie EM; Brunner LJ Pharm Res; 1997 Nov; 14(11):1613-20. PubMed ID: 9434283 [TBL] [Abstract][Full Text] [Related]
13. Induction of TNF-alpha and MnSOD by endotoxin: effect of E5531, a synthetic non-toxic lipid A analog. White JE; Tsan MF J Endotoxin Res; 2000; 6(4):329-35. PubMed ID: 11521054 [TBL] [Abstract][Full Text] [Related]
14. E5531, a pure endotoxin antagonist of high potency. Christ WJ; Asano O; Robidoux AL; Perez M; Wang Y; Dubuc GR; Gavin WE; Hawkins LD; McGuinness PD; Mullarkey MA Science; 1995 Apr; 268(5207):80-3. PubMed ID: 7701344 [TBL] [Abstract][Full Text] [Related]
15. Lipoproteins and lipoprotein metabolism. A dynamic evaluation of the plasma fat transport system. Eisenberg S Klin Wochenschr; 1983 Feb; 61(3):119-32. PubMed ID: 6843039 [TBL] [Abstract][Full Text] [Related]
16. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Bryant CE; Ouellette A; Lohmann K; Vandenplas M; Moore JN; Maskell DJ; Farnfield BA Vet Immunol Immunopathol; 2007 Apr; 116(3-4):182-9. PubMed ID: 17320193 [TBL] [Abstract][Full Text] [Related]
17. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Hughes TA; Gaber AO; Montgomery CE Ther Drug Monit; 1991 Jul; 13(4):289-95. PubMed ID: 1780959 [TBL] [Abstract][Full Text] [Related]
18. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Lagrost L; Gandjini H; Athias A; Guyard-Dangremont V; Lallemant C; Gambert P Arterioscler Thromb; 1993 Jun; 13(6):815-25. PubMed ID: 8499401 [TBL] [Abstract][Full Text] [Related]
19. Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitro. Rajaram OV; Barter PJ Biochim Biophys Acta; 1985 Jun; 835(1):41-9. PubMed ID: 4005275 [TBL] [Abstract][Full Text] [Related]
20. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]